Grant: Doctoral Research Award: Canada Graduate Scholarships
McMaster University
$105,000.00
A comprehensive investigation of the physiological trade-offs associated with carbapenem-resistance in Acinetobacter baumannii
EF 2023-24
Résumé
Bacterial antimicrobial resistance (AMR), which occurs when bacteria undergo changes that reduce the efficacy of drugs designed to treat infections, is a critical threat to public health. It is predicted that by 2050, AMR could kill 10 million people annually. One of the most important antibiotics for treating bacterial infections is carbapenems. Carbapenems are typically reserved for multidrug-resistant bacteria; however, a significant increase in carbapenem use over the last decade has led to the emergence of carbapenem-resistant bacteria, raising mortality and healthcare costs. Infections caused by carbapenem-resistant Acinetobacter baumannii (CRA) pose an urgent threat to hospitalized patients. As such, there is a critical need to develop new approaches to treat CRA. One of the primary ways that bacteria acquire resistance to carbapenems is through the transfer of carbapenemases, which are enzymes that break down the backbone of carbapenem antibiotics. Expressing resistance genes, such as carbapenemases, requires a lot of effort and resources, which comes at a cost to the host bacterium. This project aims to identify the resources, and specifically the molecular pathways required to express carbapenemase genes in A. baumannii and, subsequently, target these systems to treat CRA. We will investigate genes that are required explicitly for the growth of CRA in conditions that reflect the lower respiratory tract environment commonly associated with CRA infections, including mouse lung infection models. Next, we will aim to identify novel compounds that inhibit these essential genes and, therefore, reduce the growth of CRA. Overall, infections caused by CRA are of particular concern because they are frequently tricky to treat with available antibiotics. This work aims to uncover novel ways to treat CRA infections, ultimately contributing to the fight against antimicrobial resistance and protecting public health on a global scale.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
496459
Name
Tu Megan M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
A comprehensive investigation of the physiological trade-offs associated with carbapenem-resistance in Acinetobacter baumannii
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Antibiotic Discovery; Antibiotic Resistance; Bacterial Infection; Carbapenems; Fitness Cost; Pathogenesis
Abstract
Bacterial antimicrobial resistance (AMR), which occurs when bacteria undergo changes that reduce the efficacy of drugs designed to treat infections, is a critical threat to public health. It is predicted that by 2050, AMR could kill 10 million people annually. One of the most important antibiotics for treating bacterial infections is carbapenems. Carbapenems are typically reserved for multidrug-resistant bacteria; however, a significant increase in carbapenem use over the last decade has led to the emergence of carbapenem-resistant bacteria, raising mortality and healthcare costs. Infections caused by carbapenem-resistant Acinetobacter baumannii (CRA) pose an urgent threat to hospitalized patients. As such, there is a critical need to develop new approaches to treat CRA. One of the primary ways that bacteria acquire resistance to carbapenems is through the transfer of carbapenemases, which are enzymes that break down the backbone of carbapenem antibiotics. Expressing resistance genes, such as carbapenemases, requires a lot of effort and resources, which comes at a cost to the host bacterium. This project aims to identify the resources, and specifically the molecular pathways required to express carbapenemase genes in A. baumannii and, subsequently, target these systems to treat CRA. We will investigate genes that are required explicitly for the growth of CRA in conditions that reflect the lower respiratory tract environment commonly associated with CRA infections, including mouse lung infection models. Next, we will aim to identify novel compounds that inhibit these essential genes and, therefore, reduce the growth of CRA. Overall, infections caused by CRA are of particular concern because they are frequently tricky to treat with available antibiotics. This work aims to uncover novel ways to treat CRA infections, ultimately contributing to the fight against antimicrobial resistance and protecting public health on a global scale.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tu, Megan M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~